WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 462440
Description: UC-514321, a structural analog of NSC370284 with higher activity, directly targets STAT3/5 and represses TET1 expression, but not TET2 or TET3. UC-514321 has the potential to treat acute myeloid leukemia (AML) both in vitro and in vivo, with low toxicity.
MedKoo Cat#: 462440
Chemical Formula: C26H35NO5
Exact Mass: 441.2515
Molecular Weight: 441.568
Elemental Analysis: C, 70.72; H, 7.99; N, 3.17; O, 18.12
Synonym: UC-514321; UC514321; UC 514321
IUPAC/Chemical Name: 6-((3,5-di-tert-butyl-4-hydroxyphenyl)(morpholino)methyl)benzo[d][1,3]dioxol-5-ol
InChi Key: XNARHFDDQALZPZ-UHFFFAOYSA-N
InChi Code: InChI=1S/C26H35NO5/c1-25(2,3)18-11-16(12-19(24(18)29)26(4,5)6)23(27-7-9-30-10-8-27)17-13-21-22(14-20(17)28)32-15-31-21/h11-14,23,28-29H,7-10,15H2,1-6H3
SMILES Code: OC1=C(C(C)(C)C)C=C(C(C2=C(O)C=C(OCO3)C3=C2)N4CCOCC4)C=C1C(C)(C)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 441.568 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Jiang X, Hu C, Ferchen K, et al. Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia [published correction appears in Nat Commun. 2018 Feb 9;9(1):670]. Nat Commun. 2017;8(1):2099. Published 2017 Dec 13. doi:10.1038/s41467-017-02290-w